As the CEO of the Cambridge-based drug company Ironwood Pharmaceuticals, Peter Hecht sees the blurring of the lines between the two industries traditionally referred to as “biotech” and “pharmaceuticals” as a good thing.
“I think that’s one of the big trends in the industry in the last few years,” he said in an interview this week, just a few days before he heads to San Francisco for the biggest annual event for the health care industry, the JP Morgan Healthcare Conference. “We’re all trying to make therapies to change patients lives.”
